We have been infored that BioMarin has named it's gene therapy prodict. It was named Valrox but the new commercial name is Roctavian. We expect it to be approved by August 21, 2020.
HemoAware Founder, Jesse John Francis Clark, made a video a couple of months ago explaining BioMarin's gene therapy product.
In addition to Clark's concerns as indicated in the above video, before you can get on BioMarin's Roctavian, you need to take immune suppresents so your body can take the gene therapy. In the age of COVID, patients need to boost thier immune system, not surpress it.